Cancerous disease modifying antibodies

Details Cancerous disease modifying antibodies Cancerous disease modifying antibodies

C - Chemistry, Metallurgy

12

P

C12P 21/08 (2006.01) A61K 39/395 (2006.01) A61P 35/00 (2006.01) C07K 16/18 (2006.01) C07K 16/30 (2006.01) C07K 16/46 (2006.01) C12N 5/16 (2006.01) G01N 33/557 (2006.01) G01N 33/574 (2006.01)

Patent

CA 2617447

The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.

L'invention concerne un procédé destiné à produire des anticorps modifiant le cancer chez un patient au moyen d'un nouveau paradigme de criblage. Par séparation des anticorps anticancéreux au moyen de la cytotoxicité des cellules cancéreuses en tant qu'événement cible, le procédé rend possible la production d'anticorps anticancéreux à objectifs thérapeutique et diagnostique. Les anticorps peuvent être utilisés afin de faciliter la stadification et le diagnostic d'un cancer, et peuvent être utilisés afin de traiter des tumeurs primaires et des métastases tumorales. Les anticorps anticancéreux peuvent être conjugués à des toxines, des enzymes, des composés radioactifs et des cellules hématogènes.

Affiliated with

Also associated with

Rating

Cancerous disease modifying antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cancerous disease modifying antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancerous disease modifying antibodies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1833227